Early therapy with lyposomal amphotericin B (L-AMB) for chronic pulmonary aspergillosis
Not Applicable
- Conditions
- Chronic pulmonary aspergillosis
- Registration Number
- JPRN-UMIN000007666
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who received L-AMB within one month before the time of enrollment 2.Patients who newly started antifungal agents within three month before the time of enrollment 3.Patients with simple aspergilloma, invasive pulmonary aspergillosis, or allergic bronchopulmonary aspergollosis 4.Pregnant patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical and radiological response at three months after the end of treatment.
- Secondary Outcome Measures
Name Time Method Clinical and radiological response at the end of treatment. Clinical and radiological response at six months after the end of treatment.